GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2009

Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis

  • Galapagos and Merck & Co. expanded their existing global collaboration in metabolic diseases to cover the development of new small molecule candidates against atherosclerosis. The original deal, signed in January, covered obesity and diabetes.

    The wider collaboration could see Galapagos’ research, regulatory, and sales milestone payments double to over E400 million, or roughly $596.03 million.

    Under terms of the expanded agreement, Galapagos will use its target discovery platform to identify and validate novel targets in all three indications. The company will also be responsible for the discovery of new drug candidates against these targets.

    Merck will have an exclusive option to license each candidate for clinical development and commercialization worldwide. Galapagos is eligible to receive royalties upon commercialization of any products covered under the agreement.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »